Clinical Significance of a Gene Signature Generated from Tumor Budding Grade in Colon Cancer-Reference-Cited by-同舟云学术

Clinical Significance of a Gene Signature Generated from Tumor Budding Grade in Colon Cancer

Published:2020-04-23 Issue:10 Volume:27 Page:4044-4054
ISSN:1068-9265
Container-title:Annals of Surgical Oncology
language:en
Short-container-title:Ann Surg Oncol

Author:

Shinto Eiji,Yoshida Yuichiro,Kajiwara Yoshiki,Okamoto Koichi,Mochizuki Satsuki,Yamadera Masato,Shiraishi Takehiro,Nagata Ken,Tsuda Hitoshi,Hase Kazuo,Kishi Yoji,Ueno Hideki

Funder

The research and development fund of Sysmex Corporation

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Surgery

Link

https://link.springer.com/content/pdf/10.1245/s10434-020-08498-3.pdf

Reference27 articles.

1. O’Connell MJ, Lavery I, Yothers G, et al. Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J Clin Oncol. 2010;28:3937–44.

2. Gray RG, Quirke P, Handley K, et al. Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. J Clin Oncol. 2011;29:4611–9.

3. Venook AP, Niedzwiecki D, Lopatin M, et al. Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581. J Clin Oncol. 2013;31:1775–81.

4. Yamanaka T, Oki E, Yamazaki K, et al. 12-Gene recurrence score assay stratifies the recurrence risk in stage II/III colon cancer with surgery alone: the SUNRISE Study. J Clin Oncol. 2016;34:2906–13.

5. Yothers G, O’Connell MJ, Lee M, et al. Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin. J Clin Oncol. 2013;31:4512–9.

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. BEST: a web application for comprehensive biomarker exploration on large-scale data in solid tumors;Journal of Big Data;2023-11-01

2. Potential Theranostic Roles of SLC4 Molecules in Human Diseases;International Journal of Molecular Sciences;2023-10-13

3. ASO Author Reflections: Practical Utility of Molecular Budding Signature—An Objective Gene Classification System as a Marker of Recurrence Risk;Annals of Surgical Oncology;2023-05-23

4. Enhanced Clinical Utility of Molecular Budding Signature as a Recurrence Risk Determinant in Stage II and III Colon Cancer Patients;Annals of Surgical Oncology;2023-05-08

5. RUNX2 and Cancer;International Journal of Molecular Sciences;2023-04-10